Jazz Pharmaceuticals stock falls 2.43 percent as guidance rises

Published on 09/29/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jazz Pharmaceuticals stock posted Q2 revenue of USD 1.21 billion, up 16 percent, in Q2 2026. The Actio Biosciences acquisition added a USD 820 million epilepsy bet on September 15, 2026.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals stock (ISIN IE00B4Q5ZN47) was trading at EUR 204.40 at Lang & Schwarz on September 29, 2026 at 8:44 p.m. CEST, down 2.43 percent from the prior close of EUR 209.50. The move comes as the company balances faster revenue growth against acquisition spending and an adjusted earnings miss in Q2 2026.

Revenue grows while EPS misses

According to Stock Titan, Jazz reported Q2 2026 revenue of USD 1.21 billion, up 16 percent from the prior-year quarter. Non-GAAP adjusted EPS was USD 5.71, below the USD 6.04 consensus estimate, while GAAP diluted EPS reached USD 2.78.

The comparison is important for investors: sales beat the USD 1.11 billion consensus estimate, but acquired in-process research and development expenses of USD 77 million reduced adjusted EPS by USD 0.94. The result points to strong commercial execution with acquisition-related pressure still visible in profitability.

Guidance rises after the strong quarter

Jazz raised its 2026 total revenue guidance to USD 4.60 billion-USD 4.75 billion from USD 4.25 billion-USD 4.50 billion, according to Yahoo Finance. The company expects rare sleep revenue of USD 2.03 billion-USD 2.13 billion, while adjusted SG&A guidance increased to USD 1.33 billion-USD 1.37 billion.

At a September 9, 2026 Wells Fargo conference, Investing.com reported that Xywav added 525 net patients in Q2 and that Epidiolex revenue reached USD 292 million, up 16 percent. Management also lifted Ziihera peak sales potential to USD 3 billion-USD 5 billion from more than USD 2 billion.

Acquisition adds epilepsy potential

Jazz completed its acquisition of Actio Biosciences on September 15, 2026, for USD 820 million upfront, according to the company's investor-relations release. The deal adds ABS-1230, a clinical-stage KCNT1 inhibitor for rare epilepsy, to Jazz's neuroscience portfolio and follows the company's stated strategy of expanding through rare-disease assets.

Stock trades near its yearly midpoint

Jazz was trading at EUR 204.40 at Lang & Schwarz on September 29, 2026 at 8:44 p.m. CEST, versus EUR 209.50 at the prior close. On Nasdaq, the finance quote showed USD 231.42 at 2:49 p.m. EDT on September 29, 2026, with a 52-week range of USD 128.49-USD 266.38 and market capitalization of USD 14.5 billion.